We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

GlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.

Illumina is not banned from operating in the country and will continue to serve its existing customers, a company ...

Kokoris came up with the idea of solving some of the noise issue of nanopore sequencing by converting DNA into larger surrogate polymers, and he cofounded sequencing company Stratos Genomics back in ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

NGS methods typically involve the fragmentation of DNA into short segments, followed by the simultaneous sequencing of millions of these fragments. Some common NGS platforms include Illumina ...

The company said its technique—which combines aspects of DNA synthesis and nanopore ... to revolutionise the use of sequencing in research and healthcare.” Illumina maps out entry into spatial ...

being held in Florida—where the DNA sequencing giant is set to unveil more details and demonstrations—and follows up on Illumina’s recent expansions into proteomics and single-cell analysis.

The import ban on Illumina's NGS sequencers follows its placement on China's Ministry of Commerce's (MOFCOM) ‘Unreliable Entity List’ last month. Image credit: JHVEPhoto via Shutterstock.